<DOC>
	<DOCNO>NCT02136069</DOCNO>
	<brief_summary>This multicenter , Phase III , randomize , double-blind , double-dummy , parallel-group study evaluate safety , efficacy , tolerability etrolizumab compare infliximab treat participant moderate severe ulcerative colitis ( UC ) naive tumor necrosis factor ( TNF ) inhibitor . Participants randomize 1:1 ratio receive either etrolizumab 105 ( milligram ) subcutaneous ( SC ) injection [ SC ] every 4 week [ Q4W ] ) + placebo ( intravenous [ IV ] infusion Weeks 0 , 2 , 6 , every 8 week ) infliximab 5 milligrams/kilogram ( mg/kg ) IV Weeks 0 , 2 , 6 , every 8 week ) + placebo ( SC Q4W ) . Time treatment 54 week .</brief_summary>
	<brief_title>A Study Comparing Efficacy Safety Etrolizumab Infliximab Participants With Moderate Severe Ulcerative Colitis Who Are Na√Øve Tumor Necrosis Factor ( TNF ) Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Moderately severely active UC determine Mayo Clinic Score assessment ( MCS ) Naive treatment antiTNF therapy An inadequate response intolerance prior corticosteroid and/or immunosuppressant treatment Background regimen UC may include oral 5aminosalicylate ( 5ASA ) , oral corticosteroid , budenoside multimatrix system ( MMX ) , probiotic , azathioprine ( AZA ) , 6mercaptopurine ( 6MP ) , methotrexate ( MTX ) dose stable screen period Use highly effective contraception least 24 week last dose study drug A history current condition disease affect digestive tract , indeterminate colitis , suspicion ischemic , radiation microscopic colitis , Crohn 's disease , fistulas abdominal abscess , colonic mucosal dysplasia , intestinal obstruction , toxic megacolon , unremoved adenomatous colonic polyp Prior plan surgery UC Past present ileostomy colostomy Have receive nonpermitted inflammatory bowel disease ( IBD ) therapy ( include natalizumab , vedolizumab , efalizumab ) History moderate severe allergic anaphylactic/anaphylactoid reaction chimeric , human , humanized antibody ; fusion protein , murine protein ; hypersensitivity etrolizumab excipients Chronic hepatitis B C infection , Human deficiency virus ( HIV ) tuberculosis ( active latent )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>